News
We bring you up to date at all times: Discover the latest industry news from biotechnology, pharmaceuticals and life sciences. Researched by us so you don't have to.
Selected departments
Selected industries
Companies
The Who's Who of Life Sciences: Discover companies from all over the world. Here you can easily find the provider matching your search, including contact options.
Selected countries
Selected companies
Products
The first stop for your procurement process: discover innovative products for lab and process that make your everyday life easier and solve even complex challenges.
Products of selected companies
White papers
What could be better than an application problem that has already been solved by others? Tap into in-depth application knowledge from proven experts. Conveniently via download to your device.
Most read white papers
White papers of selected companies
Webinars
Exciting lectures and practical application tips via video, whenever you want: Our on-demand webinars make it possible. Make yourself comfortable and click play.
Selected webinars
Webinars of selected companies
Knowledge & education
Question. Answer. Find articles on 57,945 keywords in life science, biotech, pharma, biology and related science disciplines in the encyclopedia..
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Note
The function "Store search" is only available to registered users.
Important information
Currently, you are not logged in to my.bionity.com. Therefore, you can remember a maximum of 5 contents.
FILTER
Refine your search with the following facets to narrow down your results.
24-Oct-2018 - Amgen and Oxford Nanopore Technologies Ltd. announced Amgen's equity investment of £50 million ($66 million) in Oxford Nanopore, a privately-owned, UK-based company advancing a new generation of portable, real-time genetic sequencing technology. Oxford Nanopore has developed and brought to market ...
22-Dec-2015 - Medigene AG announced that Amgen Inc., USA, will acquire 100% of Catherex, Inc., USA, a spin-off of Medigene. As a main shareholder of Catherex, Medigene Inc., USA, is entitled to approximately 40% of payments to be made by Amgen. The Company was informed about the execution of the corresponding ...
20-Jul-2012 - Synthon announced that it has entered into a global license agreement with Amgen Inc. and Watson Pharmaceuticals, Inc. for Synthon’s trastuzumab, being developed as a biosimilar to Herceptin®, which is currently approved for treatment of breast cancer and gastric cancer. Earlier this year Synthon ...
First Patient Randomized Marks Start of Phase 3 Program to Evaluate Safety and Efficacy of CDP7851/AMG 785 in Women With Postmenopausal Osteoporosis
05-Apr-2012 - UCB and Amgen announced the start of their sclerostin antibody (CDP7851/AMG 785) Phase 3 clinical trial program for the treatment of postmenopausal osteoporosis."We look forward to working with UCB on the CDP7851/AMG 785 Phase 3 program," said Sean E. Harper, M.D., executive vice president of ...
Program Will Help Increase Student Interest and Achievements in Science in France, Germany, Ireland and Poland
01-Mar-2012 - The Amgen Foundation and European Schoolnet launched the "Amgen Science Teacher Training Initiative" in France, Germany, Ireland and Poland.The Amgen Science Teacher Training Initiative provides professional development for secondary school science teachers to help them incorporate hands-on ...
All-Cash Transaction Values Micromet at $1.16 Billion
31-Jan-2012 - Amgen and Micromet, Inc.announced that the companies have entered into a definitive merger agreement under which Amgen will acquire Micromet, a biotechnology company founded in Germany, for $11 per share in cash. The transaction, which values Micromet at approximately $1.16 billion, was ...
Maximum deal value of EUR 695 million plus royalties and development cost reimbursement
15-Jul-2011 - Micromet, Inc. announced that it has entered into a collaboration agreement with Amgen Inc. for the research of BiTE antibodies against three undisclosed solid tumor targets. Amgen will have the right to pursue development and commercialization of BiTE antibodies against up to two of these ...
28-Apr-2011 - UCB and Amgen announced positive top-line results from their Phase 2 clinical study comparing sclerostin-antibody CDP7851/AMG785 to placebo in postmenopausal women with low bone mineral density (BMD) for the treatment of postmenopausal osteoporosis (PMO).This Phase 2 study met its primary ...
Acquisition of a Potential, First-in-Class Cancer Therapeutic in Late-Stage Clinical Trials for the Treatment of Advanced Melanoma and Head and Neck Cancer
26-Jan-2011 - Forbion Capital Partners announced that Amgen and Biovex, Inc. have entered into a definitive acquisition agreement where Amgen has agreed to acquire BioVex Group, Inc., a privately held biotechnology company that has two biologics in clinical development, including BioVex’s lead product ...
27-Dec-2010 - Galapagos NV announced that its BioFocus service division has extended its contract with Amgen for 2011 and 2012, with an expansion to include target discovery and validation services. Under the terms of the extended agreement, Galapagos will receive €2.0 M ($2.6 M) in research fees for the ...
© 1997-2024 LUMITOS AG, All rights reserved